Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency

P Mangin, CL Yap, C Nonne, SA Sturgeon, I Goncalves… - Blood, 2006 - ashpublications.org
P Mangin, CL Yap, C Nonne, SA Sturgeon, I Goncalves, Y Yuan, SM Schoenwaelder
Blood, 2006ashpublications.org
Fibrillar collagens are among the most potent activators of platelets and play an important
role in the initiation of thrombosis. The glycoprotein VI (GPVI)/FcRγ-chain complex is a
central collagen receptor and inhibitors of GPVI produce a major defect in arterial
thrombogenesis. In this study we have examined arterial thrombus formation in mice lacking
the GPVI/FcRγ-chain complex (FcRγ–/–). Using 3 distinct arterial thrombosis models
involving deep vascular injury, we demonstrate that deficiency of GPVI/FcRγ is not …
Abstract
Fibrillar collagens are among the most potent activators of platelets and play an important role in the initiation of thrombosis. The glycoprotein VI (GPVI)/FcRγ-chain complex is a central collagen receptor and inhibitors of GPVI produce a major defect in arterial thrombogenesis. In this study we have examined arterial thrombus formation in mice lacking the GPVI/FcRγ-chain complex (FcRγ–/–). Using 3 distinct arterial thrombosis models involving deep vascular injury, we demonstrate that deficiency of GPVI/FcRγ is not associated with a major defect in arterial thrombus formation. In contrast, with milder vascular injury deficiency of GPVI/FcRγ was associated with a 30% reduction in thrombus growth. Analysis of FcRγ–/– platelets in vitro, using thrombin-dependent and -independent thrombosis models, demonstrated a major role for thrombin in overcoming the thrombosis defect associated with GPVI/FcRγ deficiency. Inhibition of thrombin in vivo produced a much greater defect in thrombus formation in mice lacking GPVI/FcRγ compared with normal controls. Similarly, thrombin inhibition produced a marked prolongation in bleeding time in FcRγ–/– mice relative to wild-type mice. Our studies define an important role for thrombin in overcoming the hemostatic and thrombotic defect associated with GPVI/FcRγ deficiency. Moreover, they raise the interesting possibility that the full antithrombotic potential of GPVI receptor antagonists may only be realized through the concurrent administration of anticoagulant agents.
ashpublications.org